80 related articles for article (PubMed ID: 20977577)
21. Induced desensitization of the insulinotropic effects of antidiabetic drugs, BTS 67 582 and tolbutamide.
McClenaghan NH; Ball AJ; Flatt PR
Br J Pharmacol; 2000 May; 130(2):478-84. PubMed ID: 10807689
[TBL] [Abstract][Full Text] [Related]
22. Pharmacological comparison between tolbutamide and two second generation hypoglycemic sulfonylureas (glibenclamide and glisoxepide).
Loubatiéres A; Mariani MM; Ribes G; Alric R
Acta Diabetol Lat; 1973; 10(2):261-82. PubMed ID: 4200675
[No Abstract] [Full Text] [Related]
23. The effect of oral sulphonylureas on blood glucose and insulin.
Adadevoh BK; Bolodeoku JO
Ghana Med J; 1973 Dec; 12(4):360-5. PubMed ID: 4282692
[No Abstract] [Full Text] [Related]
24. The ability of a new hypoglycaemic agent, A-4166, compared to sulphonylureas, to increase cytosolic Ca2+ in pancreatic beta-cells under metabolic inhibition.
Fujitani S; Okazaki K; Yada T
Br J Pharmacol; 1997 Apr; 120(7):1191-8. PubMed ID: 9105692
[TBL] [Abstract][Full Text] [Related]
25. Effect of chronic rosiglitazone, metformin and glyburide treatment on beta-cell mass, function and insulin sensitivity in mZDF rats.
Atkinson LL; McDonald-Dyck C; Benkoczi C; Finegood DT
Diabetes Obes Metab; 2008 Sep; 10(9):780-90. PubMed ID: 17970758
[TBL] [Abstract][Full Text] [Related]
26. Sulphonylurea drugs no longer inhibit ATP-sensitive K+ channels during metabolic stress in cardiac muscle.
Findlay I
J Pharmacol Exp Ther; 1993 Jul; 266(1):456-67. PubMed ID: 8331572
[TBL] [Abstract][Full Text] [Related]
27. [The insulin-secreting and proliferative activity of established islet cells in the presence of sulfonylurea].
Balabolkin MI; Timofeev AV; Danilova TI; Zhuleva LIu; Ol'shanskaia AA
Biull Eksp Biol Med; 1992 Oct; 114(10):406-8. PubMed ID: 1288706
[TBL] [Abstract][Full Text] [Related]
28. [Insulin and pro-insulin secretion following intravenous administration of tolbutamide, glisoxepide and glibenclamide].
Hausmann L; Schumann G; Kaffarnik H
Arzneimittelforschung; 1978; 28(1):83-6. PubMed ID: 415745
[TBL] [Abstract][Full Text] [Related]
29. Glibenclamide is exceptional among hypoglycaemic sulphonylureas in accumulating progressively in beta-cell-rich pancreatic islets.
Hellman B; Sehlin J; Täljedal IB
Acta Endocrinol (Copenh); 1984 Mar; 105(3):385-90. PubMed ID: 6230850
[TBL] [Abstract][Full Text] [Related]
30. Prolonged exposure to homocysteine results in diminished but reversible pancreatic beta-cell responsiveness to insulinotropic agents.
Patterson S; Scullion SM; McCluskey JT; Flatt PR; McClenaghan NH
Diabetes Metab Res Rev; 2007 May; 23(4):324-34. PubMed ID: 17089371
[TBL] [Abstract][Full Text] [Related]
31. Effects of sulphonylureas on spontaneous motility and induced contractions in rat isolated uterus.
Villar A; Ivora MD; D'Ocon MP; Anselmi E
J Pharm Pharmacol; 1986 Oct; 38(10):778-80. PubMed ID: 2879004
[TBL] [Abstract][Full Text] [Related]
32. [Clinical investigations of the effect of tolbutamide and glibenclamide on pancreatic glucagon secretion (author's transl)].
Baumeister G; Wagner H; Stahl M
Klin Wochenschr; 1975 Jun; 53(12):571-4. PubMed ID: 811925
[TBL] [Abstract][Full Text] [Related]
33. Gene networks modified by sulphonylureas in beta cells: a pathway-based analysis of insulin secretion and cell death.
Magnusson NE; Dyrskjøt L; Grimm D; Wehland M; Pietsch J; Rungby J
Basic Clin Pharmacol Toxicol; 2012 Oct; 111(4):254-61. PubMed ID: 22642398
[TBL] [Abstract][Full Text] [Related]
34. Drug interactions with oral sulphonylurea hypoglycaemic drugs.
Hansen JM; Christensen LK
Drugs; 1977 Jan; 13(1):24-34. PubMed ID: 401727
[TBL] [Abstract][Full Text] [Related]
35. Effect of PGE2 on sulfonylurea induced insulin release.
Villar A; Ivorra MD; Anselmi E
J Physiol (Paris); 1987; 82(1):12-7. PubMed ID: 3123643
[TBL] [Abstract][Full Text] [Related]
36. [Comparative use of gliquidone and tolbutamide administered intravenously].
Zilker T; Lüders L; Bottermann P
MMW Munch Med Wochenschr; 1975 Sep; 117(36):1421-2. PubMed ID: 126376
[No Abstract] [Full Text] [Related]
37. The effects of tolbutamide and glibenclamide on intestinal glucose absorption.
Teale JD; Love AH
Biochem Pharmacol; 1972 Jul; 21(13):1839-48. PubMed ID: 4630399
[No Abstract] [Full Text] [Related]
38. β-Cell-intrinsic β-arrestin 1 signaling enhances sulfonylurea-induced insulin secretion.
Barella LF; Rossi M; Zhu L; Cui Y; Mei FC; Cheng X; Chen W; Gurevich VV; Wess J
J Clin Invest; 2019 Jun; 129(9):3732-3737. PubMed ID: 31184597
[TBL] [Abstract][Full Text] [Related]
39. Enhancement of homocysteine toxicity to insulin-secreting BRIN-BD11 cells in combination with alloxan.
Scullion SM; Gurgul-Convey E; Elsner M; Lenzen S; Flatt PR; McClenaghan NH
J Endocrinol; 2012 Aug; 214(2):233-8. PubMed ID: 22582095
[TBL] [Abstract][Full Text] [Related]
40. Combination Therapy of Nifedipine and Sulphonylureas Exhibits a Mutual Antagonistic Effect on the Endothelial Cell Dysfunction Induced by Hyperglycemia Linked to Vascular Disease.
Wang LP; Jiang Y; Yang H; Peng C; Zhang C; Tao X; Xie HH
Cell Physiol Biochem; 2016; 38(6):2337-47. PubMed ID: 27198152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
